目的：探讨米非司酮预防子宫肌瘤患者肌瘤切除术后复发的有效性及安全性。方法选取2012年3月~2014年6月海南省万宁市人民医院收治的86例子宫肌瘤患者作为研究对象，根据随机数字表法将其均分为观察组和对照组，两组均行子宫肌瘤切除术治疗，对照组术后不予以任何药物治疗，观察组术后接受米非司酮治疗，比较两组临床疗效。结果观察组术后6个月及术后2年复发率明显低于对照组，差异均有统计学意义(P<0.05或P<0.01)；观察组术后平均复发时间为(15.23±5.64)个月，长于对照组的(6.14±4.15)个月，差异有统计学意义(P<0.05)；观察组术后阴道出血量明显少于对照组，月经恢复时间长于对照组，差异均有高度统计学意义(P<0.01)；观察组术后血红蛋白水平明显高于对照组，卵泡刺激素、雌二醇及孕酮水平均低于对照组，差异均有高度统计学意义(P<0.01)；观察组不良反应发生率为4.65%，低于对照组的30.23%，差异有统计学意义(P<0.05)。结论米非司酮预防子宫肌瘤患者肌瘤切除术后复发疗效显著，安全性高，可在临床上推广。%Objective To explore the effectiveness and safety of Mifepristone on the recurrence prevention of patients with myoma after myomectomy. Methods From March 2012 to June 2014, in the People's Hospital of Wanning City 86 patients with myoma were equally divided into control group and observation group, asccording to random number table method. The two groups were treated with myomectomy, patients in control group were not given any drug treatment af-ter myomectomy, and patients in the observation group were accepted treatment of Mifepristone after myomectomy. The clinical efficacy of two groups were compared. Results The recurrence rates of observation group after 6 months and 2 years were significantly lower than control group, the differences were statistically significant (P< 0.05 or P< 0.01);The average postoperative recurrence time were (15.23±5.64) months, longer than the control group [(6.14±4.15) months], the difference was statistically significant (P<0.05);the vagina bleeding quantity of observation group signifi-cantly was less than control group, and menstrual recovery time was longer than the control group, the differences were statistically significant (P < 0.01); the hemoglobin levels of observation group was significantly higher than control group, FSH, E2 and P levels were significantly lower than control group, the differences were statistically significant (P<0.01);the incidence of adverse reactions of observation group was 4.65%, lower than the control group (30.23%), the difference was statistically significant (P< 0.05). Conclusion Oral Mifepristone is an effective and safe treatment in preventing recurrence of patients with myoma after myomectomy. It can be applied in clinical practice.
展开▼
